IL17A and psoriasis: Despite psoriasis studies on pathogenesis had clarified several aspects, from a therapeutic point of view [39,40,41], anti-psoriatic biological drugs antagonize TNF-α, IL-17/IL-23 pathway and, recently, also JAKs.